INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31401, 1172, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31402, 29488, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31403, 237, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31404, 738, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31405, 750, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31406, 7003, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31407, 9563, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31408, 11867, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31409, 15493, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31410, 15494, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31411, 29596, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31412, 29597, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31413, 29598, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31414, 29599, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31415, 237, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31416, 738, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31417, 750, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31418, 7003, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31419, 9563, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31420, 11867, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31421, 15493, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31422, 15494, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31423, 29596, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31424, 29597, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31425, 29598, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31426, 29599, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31427, 237, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31428, 738, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31429, 750, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31430, 7003, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31431, 9563, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31432, 11867, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31433, 15493, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31434, 15494, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31435, 29596, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31436, 29597, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31437, 29598, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31438, 29599, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31439, 237, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31440, 738, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31441, 750, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31442, 7003, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31443, 9563, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31444, 11867, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31445, 15493, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31446, 15494, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31447, 29596, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31448, 29597, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31449, 29598, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31450, 29599, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31451, 237, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31452, 738, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31453, 750, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31454, 7003, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31455, 9563, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31456, 11867, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31457, 15493, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31458, 15494, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31459, 29596, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31460, 29597, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31461, 29598, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31462, 29599, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31463, 1699, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31464, 15463, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31465, 7018, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31466, 12493, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31467, 18674, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31468, 28247, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31469, 28248, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31470, 29463, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31471, 29506, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31472, 29508, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31473, 29511, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31474, 7018, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31475, 12493, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31476, 18674, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31477, 28247, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31478, 28248, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31479, 29463, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31480, 29506, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31481, 29508, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31482, 29511, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31483, 0, 'Vorapaxar', 'Hemorrhage', 'Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer.  In other patients, consider the underlying risk of bleeding before initiating therapy.  General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications.  The use of warfarin and other anticoagulants should be avoided.  Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31484, 0, 'Vorapaxar', 'Ischemic Stroke', 'Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding.  The risk of intracranial bleeding is higher in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31485, 0, 'Vorapaxar', 'Liver Diseases', 'No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment.  Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31486, 0, 'Vorinostat', 'Thromboembolism', 'The use of vorinostat may cause pulmonary embolism and deep vein thrombosis.  It is recommended to monitor for signs and symptoms of these events, particularly in patients with a prior history of thromboembolic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31487, 0, 'Vorinostat', 'Diabetes Mellitus', 'The use of vorinostat may cause hyperglycemia.  It is recommended to monitor serum glucose every 2 weeks during the first 2 months of therapy and monthly thereafter.  Care should be exercised when using this agent in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31488, 0, 'Vorinostat', 'Gastrointestinal Diseases', 'The use of vorinostat may cause gastrointestinal disturbances.  It is recommended to adequately control any preexisting nausea, vomiting, and diarrhea prior to beginning treatment with vorinostat.  Fluid and electrolytes should be replaced to prevent dehydration and the use of antiemetic and antidiarrheal medications may be appropriate.  Correct hypokalemia and hypomagnesemia prior to administration of vorinostat.  Monitor potassium and magnesium more frequently in symptomatic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31489, 0, 'Vorinostat', 'Liver Failure', 'Compared to patients with normal liver function, AUC increases of 50 to 66% were observed in patients with hepatic impairment.  It is recommended to reduce the starting dose of vorinostat to 300 mg orally once daily with food in patients with mild to moderate hepatic impairment (bilirubin 1 to 3  ULN or AST greater than ULN).  There is insufficient evidence to recommend a starting dose for patients with severe hepatic impairment (bilirubin greater than 3  ULN).  Precautions should be instituted when using this agent in patients with liver dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31490, 0, 'Vorinostat', 'Bone Marrow Failure Disorders', 'The use of vorinostat can cause dose-related thrombocytopenia and anemia.  It is recommended to monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter.  Adjust dosage or discontinue treatment as clinically appropriate.  Care should be exercised when using this agent in patients with bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31491, 12260, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31492, 14824, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31493, 16702, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31494, 16703, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31495, 18521, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31496, 19469, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31497, 29218, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31498, 29591, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31499, 29592, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31500, 29593, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '', 'DDInter', 0);
